Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study

被引：4
|
作者：
Daud, Aizati N. A. [1 ,2 ]
Bergman, Jorieke E. H. [3 ]
Kerstjens-Frederikse, Wilhelmina S. [3 ]
van der Vlies, Pieter [3 ]
Hak, Eelko [1 ]
Berger, Rolf M. F. [4 ]
Groen, Henk [5 ]
Wilffert, Bob [1 ,6 ]
机构：
[1] Univ Groningen, Groningen Res Inst Pharm, Dept Pharm, Unit PharmacoTherapy Epidemiol & Econ, Groningen, Netherlands
[2] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Cardiol, Groningen, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands
[6] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
来源：
PHARMACOGENOMICS | 2017年 / 18卷 / 10期
关键词：
gene-environment interaction; heart defects; pharmacogenetics; serotonin reuptake inhibitors; teratogenicity; GENE-ENVIRONMENT INTERACTIONS; ABCB1; GENE; ANTIDEPRESSANT THERAPY; PROMOTER POLYMORPHISM; CLINICAL-RESPONSE; PREGNANT-WOMEN; P-GLYCOPROTEIN; MEDICATION USE; RISK-FACTORS; 3B RECEPTOR;
D O I：
10.2217/pgs-2017-0036
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim: To explore the role of pharmacogenetics in determining the risk of congenital heart anomalies (CHA) with prenatal use of serotonin reuptake inhibitors. Methods: We included 33 case-mother dyads and 2 mother-only (child deceased) cases of CHA in a case-only study. Ten genes important in determining fetal exposure to serotonin reuptake inhibitors were examined: CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC6A4, HTR1A, HTR1B, HTR2A and HTR3B. Results: Among the exposed cases, polymorphisms that tended to be associated with an increased risk of CHA were SLC6A4 5-HTTLPR and 5-HTTVNTR, HTR1A rs1364043, HTR1B rs6296 and rs6298 and HTR3B rs1176744, but none reached statistical significance due to our limited sample sizes. Conclusion: We identified several polymorphisms that might potentially affect the risk of CHA among exposed fetuses, which warrants further investigation.
引用
收藏
页码：987 / 1001
页数：15
相关论文
共 50 条
  • [31] Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data
    Oberlander, Tim F.
    Warburton, William
    Misri, Shaila
    Riggs, Wayne
    Aghajanian, Jaafar
    Hertzman, Clyde
    BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2008, 83 (01) : 68 - 76
  • [32] Selective Serotonin Reuptake Inhibitors and Congenital Heart Anomalies: Comparative Cohort Studies of Women Treated Before and During Pregnancy and Their Children
    Petersen, Irene
    Evans, Stephen J.
    Gilbert, Ruth
    Marston, Louise
    Nazareth, Irwin
    JOURNAL OF CLINICAL PSYCHIATRY, 2016, 77 (01) : E36 - +
  • [33] Pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions
    Thomas, Kelan L. H.
    Ellingrod, Vicki L.
    PHARMACOTHERAPY, 2009, 29 (07): : 822 - 831
  • [34] Perceptual interference processing in preschool children, with and without prenatal exposure to selective serotonin reuptake inhibitors
    Tone Kristine Hermansen
    Santeri Yrttiaho
    Espen Røysamb
    Annika Melinder
    Psychopharmacology, 2017, 234 : 339 - 351
  • [35] Perceptual interference processing in preschool children, with and without prenatal exposure to selective serotonin reuptake inhibitors
    Hermansen, Tone Kristine
    Yrttiaho, Santeri
    Roysamb, Espen
    Melinder, Annika
    PSYCHOPHARMACOLOGY, 2017, 234 (03) : 339 - 351
  • [36] Infant and Childhood Neurodevelopmental Outcomes Following Prenatal Exposure to Selective Serotonin Reuptake Inhibitors (SSRIs)
    Malm, Heli
    Artama, Miia
    Brown, Alan S.
    Gissler, Mika
    Gyllenberg, David
    Hinkka-Yli-Salomaki, Susanna
    McKeague, Ian
    Sourander, Andre
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 141 - 142
  • [37] Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: The relevance of dose
    Roca, A.
    Garcia-Esteve, Ll.
    Imaz, M. L.
    Torres, A.
    Hernandez, S.
    Botet, F.
    Gelabert, E.
    Subira, S.
    Plaza, A.
    Valdes, M.
    Martin-Santos, R.
    JOURNAL OF AFFECTIVE DISORDERS, 2011, 135 (1-3) : 208 - 215
  • [38] Autism spectrum disorder and prenatal exposure to selective serotonin reuptake inhibitors: Need for further analysis
    Ou, Jian-Jun
    Li, Ya-Min
    REPRODUCTIVE TOXICOLOGY, 2017, 67 : 146 - 147
  • [39] Prenatal exposure to selective serotonin reuptake inhibitors and non-verbal cognitive functioning in childhood
    El Marroun, Hanan
    White, Tonya J.
    Fernandez, Guillen
    Jaddoe, Vincent W. V.
    Verhulst, Frank C.
    Stricker, Bruno H.
    Tiemeier, Henning
    JOURNAL OF PSYCHOPHARMACOLOGY, 2017, 31 (03) : 346 - 355
  • [40] Autism spectrum disorder and prenatal exposure to selective serotonin reuptake inhibitors: Need for further analysis
    Kobayashi, Tohru
    Matsuyama, Tasuku
    Takeuchi, Masanobu
    Ito, Shinya
    REPRODUCTIVE TOXICOLOGY, 2017, 67 : 148 - 148
12345